New drug cocktail shows promise for rare amyloid disease
NCT ID NCT03283917
First seen Mar 04, 2026 · Last updated Jun 19, 2026 · Updated 18 times
Summary
This early-stage trial is testing the safety and best dose of a three-drug combination—daratumumab, ixazomib, and dexamethasone—in 21 people with AL amyloidosis, a rare disease where abnormal proteins build up in organs. The goal is to find a dose that limits side effects while effectively targeting the underlying plasma cell disorder. Researchers will also track how well the treatment controls the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PRIMARY AMYLOIDOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab, ixazomib, and dexamethasone
What this could lead to
If successful, this could establish a safer and more effective combination therapy for AL amyloidosis, potentially improving blood-related responses and survival.
What could go wrong
This is a very early Phase 1 trial with only 21 participants, so results may not apply broadly. Side effects from the drug combination could be significant, and the study is not designed to prove long-term benefit.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.